期刊文献+

两种同步放化疗方案治疗Ⅰb2~Ⅳa期子宫颈鳞癌的临床分析 被引量:12

Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage I b2 to Ⅳ a squamous cell carcinoma of the uterine cervix
原文传递
导出
摘要 目的比较分析Ⅰb2~Ⅳa期宫颈鳞癌患者同步放化疗中两种含铂化疗方案的疗效和安全性。方法回顾性分析2007年11月至2011年11月北京大学肿瘤医院收治的接受同步放化疗的宫颈鳞癌患者共146例的临床病理资料,根据同步放化疗中化疗方案的不同分为两组:铂类单药每周方案化疗(单药化疗组)59例,氟尿嘧啶+铂类联合3周方案化疗(联合方案组)87例。治疗结束3个月后进行评效,比较两组患者的近期疗效、生存率和毒性反应发生情况。结果单药化疗组和联合方案组患者的有效率分别为97%(57/59)、93%(81/87),两组比较,差异无统计学意义(P=0.249)。单药化疗组、联合方案组患者的5年总生存率分别为61.2%和69.5%,5年无进展生存率分别为43.3%和24.4%,5年局部复发率分别为11.8%和9.8%,5年远处转移率分别为29.4%和38.7%,分别比较,差异均无统计学意义(P〉0.05)。毒性反应发生情况:联合方案组的消化道毒性反应(恶心、呕吐)发生率明显高于单药化疗组[分别为78%(68/87)、51%(30/59),P〈0.01],且其贫血较单药化疗组更常见[贫血发生率分别为53%(46/87)、25%(15/59),P=0.019];但急性和晚期放射性直肠炎、膀胱炎及其他常见毒性反应的发生率比较,差异无统计学意义(P〉0.05)。结论两种同步放化疗方案的疗效相当,铂类单药每周方案的毒性反应发生率明显低于含铂的3周联合方案。 Objective To compare the clinical efficacy and safety of two chemotherapy regimens for concurrent ehemoradiotherapy in patients with stage I b2 to IV a squamous cell carcinoma of the uterine cervix. Methods Between November 2007 and November 2011, 146 patients with stage I b2 to IV a squamous cell carcinoma of the uterine cervix who received concurrent ehemoradiotherapy in Peking University Cancer Hospital were analyzed. All cases were divided into two groups according to the different chemotherapy regimens during radiation therapy, the group receiving radiotherapy concomitant with weekly cisplatin or nedaplatin alone ( platinum alone group, n = 59 ) , the group receiving radiotherapy concomitant with cisplatin plus fluorouracil or nedaplatin plus tegafur every 3 weeks ( combined group, n = 87 ). There were no statistical difference in the clinical and pathological characteristics between the two groups. Results Patients were evaluated by pelvic examination and pelvic MRI after chemoradiotherapy for 3 months according to WHO criteria. The response rate were respectively 97% (57/59) and 93% (81/87) in platinum alone group and combined group, in which there was no significant difference ( P = 0. 249 ). The five-year overall survival and the five-year progression-free survival of platinum alone group and combined group were respectively 61.2% versus 69.5% ( P 〉 0.05) and 43.3% versus 24.4% ( P 〉 0.05 ). There were also no statistically significant differences between platinum alone group and combined group in the five- year local recurrence rate and five-year distant metastasis ( 11.8% versus 9. 8% , 29. 4% versus 38.7% ; all P 〉 0. 05 ). Acute gastrointestinal toxicities (nausea and vomiting) in combined group were exactly higher than that in the other group [78% (68/87) versus 51% (30/59), P 〈0.01]. Moreover, anaemia was slightly more common in combined group [ 53% ( 46/87 ) versus 25% ( 15/59 ), P = 0. 019 ]. However, the occurrence rate of the acute or late proctitis and cystitis did not reveal difference between two groups ( P 〉 O. 05 ). Conclusions Both concurrent chemoradiotherapy regimens had similar efficacy on cervical cancer patients with stage I b2 to IVa. But the toxicity was lower in patients with weekly platinum than those with platinum-based combined regimens during radiation therapy.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2013年第10期763-767,共5页 Chinese Journal of Obstetrics and Gynecology
关键词 宫颈肿瘤癌 鳞状细胞 放射疗法 调强适形 药物疗法 肿瘤治疗方案 Uterine cervical neoplasms Carcinoma, squamous cell Radiotherapy, intensity-modulated Drug therapy Antineoplastic protocols
  • 相关文献

参考文献14

  • 1Keys HM, Bundy BN, Stehman FB, et al. Cisplatin radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med, 1999, 340 : 1154-1161.
  • 2Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med,1999, 340:1137-1143.
  • 3Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin- based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med, 1999, 340 : 1144-1153.
  • 4Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage ]I B-IV A carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol, 1999, 17:1339-1348.
  • 5Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol, 2000, 18 : 1606-1613.
  • 6Vale C, Tiemey JF, Stewart LA, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol, 2008, 26: 5802-5812.
  • 7Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92:205-216.
  • 8Duenas-Gonzalez A, Zarba JJ, Patel F, et al. Phase Ⅲ, open- label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage Ⅱ B to IVA carcinoma of the cervix. J Clin Oncol, 2011, 29 : 1678-1685.
  • 9Kim YS, Shin SS, Nam JH, et aL Prospective randomized comparison of monthly fluorouraeil and eisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol, 2008, 108:195-200.
  • 10Monk B J, Tewari KS, Koh WJ. Muhimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol, 2007, 25:2952-2965.

二级参考文献44

  • 1黄曼妮,吴令英,高菊珍.宫颈癌的同步放化疗[J].癌症进展,2004,2(5):320-326. 被引量:60
  • 2Rose PG, AIi S, Watkins E, et al. long- term follow- up of a randomized trial comparing concurrent single agenl cisplatin, cisplatin - based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 2007, 25: 2804-2810.
  • 3Shibata K, Kikkawa F, Suzuki Y, et al. Usefulness of preoperative chemoradiation in Jocally advanced cervical carcinoma. Gynecol Obstet Invest, 2004, 57: 93-99.
  • 4Uno T, Mitsuhashi A, Isobe K, et al. Concurrent daily cisplatin and extended- field radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer, 2008, 18:80 - 84.
  • 5Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly eisplatin concurrent with pelvic radiotherapy and high- dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol, 2008, 108: 195-200.
  • 6Torres MA, Jhingran A, Thames HD, et al. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys. 2008, 70: 118- 125.
  • 7Sumi H,Ohtsu A,Boku N,et al.A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin [J].JpnJ Clin Oncol,2000,30(9):406~409
  • 8Kaneko K,Ito H,Ito T,et al.A case of esophageal carcinoma with multiple liver metastases successfully treated with nedaplatin (NDP) and 5-fluorouracil (5-FU) combined with radiotherapy[J].Gan To Kagaku Ryoho,2001,28(6):831 ~834
  • 9Hirabayashi Y,Okada E.Combination chemotherapy with 254-S,ifosfamide and peplomycin for advanced or recurrent cervical cancer[J].Cancer,1992,71:2769 -2775
  • 10Adachi S,Ogasawara T,Yamasaki N,et al.A pilot study of nedaplatin and etoposide for recurrent gynecological malignancies [J].Oncol Rep,1998,5(4):881-884

共引文献183

同被引文献79

引证文献12

二级引证文献172

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部